IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment.
Bo HuMincheng YuXiaolu MaJia-Lei SunChenglong LiuChunyan WangSuiyi WuPei-Yao FuZhen YangYungang HeYuanyuan ZhuCheng HuangXin-Rong YangYinghong ShiShuangjian QiuHuichuan SunAndrew X ZhuJian ZhouYang XuDi ZhuJia FanPublished in: Cancer discovery (2022)
Our study supports a role of tumor glucose metabolism in IFNα-mediated antitumor immunity in HCC, and tumor-infiltrating CD27+CD8+ T cells may be a promising biomarker for stratifying patients for anti-PD-1 therapy. See related commentary by Kao et al., p. 1615. This article is highlighted in the In This Issue feature, p. 1599.